Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neurocrine (NBIX)
NASDAQ:NBIX
Neurocrine (NBIX) Stock Price & Analysis
1,197 Followers
NBIX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$89.04 - $148.37
Previous Close$142
Volume670.98K
Average Volume (3M)851.67K
Market Cap
$14.29B
Enterprise Value$13.69B
Total Cash (Recent Filing)$1.03B
Total Debt (Recent Filing)$428.40M
Price to Earnings (P/E)39.0
Beta0.38
Next Earnings
Jul 30, 2024EPS Estimate
$1.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.64
Shares Outstanding100,637,227
10 Day Avg. Volume650,884
30 Day Avg. Volume851,674
Standard Deviation0.09
R-Squared0.03
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)6.34
Price to Sales (P/S)27.74
Price to Cash Flow (P/CF)28.20
P/FCF Ratio29.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.25
Enterprise Value/Gross Profit7.41
Enterprise Value/Ebitda40.21
Forecast
1Y Price Target
$162.16Price Target Upside14.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
Neurocrine News
Bulls Say, Bears Say
Bulls Say
Drug Development And Regulatory MilestonesCrinecerfont received Breakthrough Therapy designation by the FDA, making it eligible for priority review and indicating strong underlying data supporting its efficacy.
Financial Performance And GuidanceNeurocrine maintains a strong financial position with plans to retire convertible senior notes, reflecting a commitment to strong fiscal management and mitigating shareholder dilution concerns.
Market Expansion And Sales GrowthIngrezza sales achieved sequential growth and management successfully expanded its presence in the long-term care segment, showcasing the company's ability to grow its leading product.
Bears Say
Clinical Trial ResultsTildacerfont's late-stage study results in congenital adrenal hyperplasia were disappointing, failing to meet the primary endpoint and leading to a significant drop in the company's stock value.
Drug Efficacy ConcernsDespite upcoming trial readouts for tildacerfont, the profile of the drug has been impaired, questioning its commercial positioning if approved.
Financial PerformanceEPS estimates for 2024 have been revised down from $4.80 to $4.45, reflecting changes in the financial model based on recent data.
---
Ownership Overview
16.05% Insiders
25.41% Mutual Funds
52.33% Other Institutional Investors
6.21% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NBIX FAQ
What was Neurocrine’s price range in the past 12 months?
Neurocrine lowest stock price was $89.04 and its highest was $148.37 in the past 12 months.
What is Neurocrine’s market cap?
Currently, no data Available
When is Neurocrine’s upcoming earnings report date?
Neurocrine’s upcoming earnings report date is Jul 30, 2024 which is in 74 days.
How were Neurocrine’s earnings last quarter?
Neurocrine released its earnings results on May 01, 2024. The company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $1.098 by -$0.678.
Is Neurocrine overvalued?
According to Wall Street analysts Neurocrine’s price is currently Undervalued.
Does Neurocrine pay dividends?
Neurocrine does not currently pay dividends.
What is Neurocrine’s EPS estimate?
Neurocrine’s EPS estimate is $1.11.
How many shares outstanding does Neurocrine have?
Neurocrine has 100,637,230 shares outstanding.
What happened to Neurocrine’s price movement after its last earnings report?
Neurocrine reported an EPS of $0.42 in its last earnings report, missing expectations of $1.098. Following the earnings report the stock price went up 3.992%.
Which hedge fund is a major shareholder of Neurocrine?
Among the largest hedge funds holding Neurocrine’s share is Dodge & Cox. It holds Neurocrine’s shares valued at 175M.
---
Neurocrine Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$162.16 (14.27% Upside)
$162.16 (14.27% Upside)
Blogger Sentiment
Bullish
NBIX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 11.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.1%
Last 30 Days ▲ 6.1%
Last 30 Days ▲ 6.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.67%
12-Months-Change
Fundamentals
Return on Equity
18.16%
Trailing 12-Months
Asset Growth
47.15%
Trailing 12-Months
Company Description
Neurocrine
Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.
---
NBIX Company Deck
---
NBIX Earnings Call
Q1 2024
0:00 / 0:00
---
NBIX Stock 12 Month Forecast
Average Price Target
$162.16
▲(14.27% Upside)
Technical Analysis
Best Analysts Covering NBIX
1 Year
1 Year Success Rate
26/29 ratings generated profit
1 Year Average Return
+25.92%
reiterated a buy rating 14 days ago
Copying Anupam Rama's trades and holding each position for 1 Year would result in 89.66% of your transactions generating a profit, with an average return of +25.92% per trade.
---